These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies. Jensen SB; Latysheva N; Hindberg K; Ueland T J Intern Med; 2022 Sep; 292(3):523-535. PubMed ID: 35426199 [TBL] [Abstract][Full Text] [Related]
16. Serum levels of vitamin D are not associated with future risk of venous thromboembolism. The Tromsø Study. Brodin E; Lerstad G; Grimnes G; Brækkan SK; Vik A; Brox J; Svartberg J; Jorde R; Hansen JB Thromb Haemost; 2013 May; 109(5):885-90. PubMed ID: 23446951 [TBL] [Abstract][Full Text] [Related]
17. High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism. Damoah CE; Snir O; Hindberg K; Garred P; Ludviksen JK; Brækkan SK; Morelli VM; Mollnes TE; Hansen JB; Arterioscler Thromb Vasc Biol; 2022 Sep; 42(9):1186-1197. PubMed ID: 35861070 [TBL] [Abstract][Full Text] [Related]
18. High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites. Payne AB; Miller CH; Hooper WC; Lally C; Austin HD Ethn Dis; 2014; 24(2):169-74. PubMed ID: 24804362 [TBL] [Abstract][Full Text] [Related]
19. High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: the HUNT study. Morelli VM; Snir O; Hindberg KD; Hveem K; Brækkan SK; Hansen JB Blood; 2024 Apr; 143(17):1773-1781. PubMed ID: 38211336 [TBL] [Abstract][Full Text] [Related]
20. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Robertson L; Yeoh SE; Stansby G; Agarwal R Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]